Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 8/20 | 0.38 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.32 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3115119 | 0.91 | MEN1 (0.36) | TACR1P2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL3105544 | 0.91 | FAP (0.35) | TACR1P2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL3110704 | 0.90 | TACR1 (0.34) | TACR1P2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL3104915 | 0.90 | TACR1 (0.34) | TACR1P2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL3102889 | 0.89 | EGLN1 (0.34) | TACR1P2RX7EGLN1 | |
| SCHEMBL870579 | 0.89 | MEN1 (0.36) | TACR1P2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL869923 | 0.89 | P2RX1 (0.36) | TACR1P2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL3096698 | 0.88 | FAP (0.38) | TACR1LMNA | |
| SCHEMBL3641940 | 0.88 | POLB (0.34) | TACR1P2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL872236 | 0.88 | RXRA (0.34) | TACR1P2RX1P2RX3P2RX4P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3222618-B1 | NAPTHALENE ISOXAZOLINE INVERTEBRATE PEST CONTROL AGENTS | DU PONT (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3222618-A1 | NAPTHALENE ISOXAZOLINE INVERTEBRATE PEST CONTROL AGENTS | E. I. du Pont de Nemours and Company (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-2158188-B1 | NAPHTHALENE ISOXAZOLINE INVERTEBRATE PEST CONTROL AGENTS | DU PONT (US) | 2017-04-26 | — | — | EP | disclosed |
| US-20140113943-A9 | Naphthalene Isoxazoline Invertebrate Pest Control Agents | E.I. DU PONT DE NEMOURS AND COMPANY | 2014-04-24 | — | — | US | disclosed |
| US-20130217736-A1 | Naphthalene Isoxazoline Invertebrate Pest Control Agents | DU PONT (US) | 2013-08-22 | — | — | US | disclosed |
| US-8410153-B2 | Naphthalene isoxazoline invertebrate pest control agents | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-04-02 | — | — | US | disclosed |
| US-20100254959-A1 | NAPHTHALENE ISOXAZOLINE INVERTEBRATE PEST CONTROL AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100254959-A1 | NAPHTHALENE ISOXAZOLINE INVERTEBRATE PEST CONTROL AGENTS | C1S, C1R, C9 | TACR1 983/4885P2RX1 488/4885P2RX3 277/4885 |
| US-20130217736-A1 | Naphthalene Isoxazoline Invertebrate Pest Control Agents | C1S, C1R, C9 | TACR1 983/4885P2RX1 488/4885P2RX3 277/4885 |
| US-20140113943-A9 | Naphthalene Isoxazoline Invertebrate Pest Control Agents | C1S, C1R, C9 | TACR1 983/4885P2RX1 488/4885P2RX3 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.